Introduction
============

Although significant advances have been made in the treatment of some malignancies, the prognosis of patients with metastasis tumors remains poor. Differentiating agents redirect cells toward their normal phenotype and therefore may reverse or suppress evolving malignant lesions or prevent cancer invasion. In addition, they offer a potential alternative to the classic cytostatic drugs and indeed represent an attractive target for medicinal intervention. Retinoids (vitamin A and its natural metabolites and synthetic analogs) are currently the subject of intense biological interest stimulated by the discovery and characterization of retinoid receptor and the realization of these compounds as nonsteroidal small-molecule hormones \[[@b1-scipharm-2011-79-921], [@b2-scipharm-2011-79-921]\]. *All-trans*-retinoic acid (ATRA), the biologically most active metabolite of vitamin A, plays a major role in cellular differentiation and proliferation of epithelial tissue. ATRA is being used in differentiation therapy of cancer, in cancer chemoprevention and for the treatment of acne \[[@b3-scipharm-2011-79-921]--[@b5-scipharm-2011-79-921]\]. Recently, ATRA has proven useful in cancer chemotherapy \[[@b6-scipharm-2011-79-921]--[@b8-scipharm-2011-79-921]\]. One of the most impressive effects of ATRA is on acute promyelocytic leukaemia. Treatment of acute promyelocytic leukaemia patients with high dose of ATRA resulted in complete remission \[[@b9-scipharm-2011-79-921], [@b10-scipharm-2011-79-921]\]. Furthermore, several experiments in animals have demonstrated that ATRA inhibited the induction and caused the disappearance of prostate tumors \[[@b11-scipharm-2011-79-921]\]. In spite of these encouraging results, the effects of prolonged ATRA therapy on human cancers in the clinic has been scarce and disappointing \[[@b12-scipharm-2011-79-921]\]. It has been suggested that the therapeutic effects of ATRA are undermined by its rapid in vivo metabolism and catabolism by cytochrome P450 enzyme (CYPs) \[[@b13-scipharm-2011-79-921], [@b14-scipharm-2011-79-921]\].

One of the strategies for preventing in vivo catabolism of ATRA is to inhibit the P450 enzyme(s) responsible for this process. Indeed, this seems to be an emerging approach that may yield effective agents for the chemoprevention and/or treatment of cancers \[[@b15-scipharm-2011-79-921]\]. This may create a novel class of agents known as retinoic acid metabolism blocking agents (RAMBAs). Liarozole, a P-450 inhibitor (17, 20 steroid lyase) and the first RAMBA to undergo clinical investigation, preferentially increases intratumor levels of endogenous RA, resulting in antitumor activity \[[@b16-scipharm-2011-79-921]\]. This has opened up the possibility of developing more specific inhibitors of ATRA metabolism as a novel approach to cancer treatment. In the present study a wide range of established P450 inhibitors has been screened to examine their inhibitory activity on ATRA metabolism.

Materials and Methods
=====================

Reagents
--------

*N*-benzyl-2-phenylethanamine was purchased from Aldrich Chemical Company Ltd, 2-methyl-5-phenyl-1,3-benzoxazole, 4-(4-bromophenyl)-1,2,3-thiadiazole, 5-(4-methyl-phenyl)-1,2,4-thiadiazole, 5-(3-chlorophenyl)-1,3-oxazole and 2-(thiophen-2-yl)-1,3,4-oxadiazole were obtained from Maybridge Chemical Co Ltd. (Tintagel Cornwall). Liarozole was donated by Janssen Research Foundation (Bearse Belgium). *All-trans-*retinoic acid, NADPH, butylated hydroxyanisole and all the other P-450 inhibitors were purchased from Sigma Chemical Company. \[11,12-^3^H\]-*All-trans-*retinoic acid (ATRA) was from DuPont (UK) Ltd. Formic acid, ammonium acetate and Hisafe III scintillation fluid (optiphase III) were obtained from Fisons Ltd. All solvents used for chromatography were of HPLC grade and were obtained from Rathburn Chemicals Ltd.UK. All other laboratory reagents were of analytical grade and obtained from British Drug House.

Animals
-------

Healthy male wistar rats were fasted overnight and killed by stunning.

Preparation of rat liver microsomes
-----------------------------------

Rat liver microsomes were prepared by a previously described method \[[@b17-scipharm-2011-79-921]\] and stored at −80°C.

RA Metabolism Assay
-------------------

The incubation system contained RA (3 μM, μl), NADPH (2 mM, 50 μl), inhibitor (100 μM, final concentration) in DMSO (10 μl), phosphate buffer (50 mM, pH 7.4) up to a final volume of 400 μl. The reaction was started by the addition of male rat hepatic microsomes (0.12 mg/ml, 10 μl) and the mixture incubated at 37°C. The reaction was terminated after 15 min by addition of formic acid (1% 100 μl). ^3^H.RA and its metabolites were extracted into ethyl acetate containing 0.05% (v/v) butylated hydroxyanisole (2×2 ml). The extract was dried out in vacuum at r. t. and the residue dissolved in the mobile phase used for the reverse phase. Controls (10 μl, DMSO) were also carried with each experiment.

HPLC Separation of labeled material
-----------------------------------

The assay followed a previously described one \[[@b17-scipharm-2011-79-921]\]: The column was a 10 μm C18 μ Bondapak (3.9× 300mm, Millipore) and the mobile phase was acetonitrile: water: formic acid (75:25:0.05v/v) containing 10 mM ammonium acetate. Flow rate was 1.2 ml.Min^−1^. Eluted ^3^H compounds were detected on line by a model 970 detector (Reeve) using Hisafe III scintillation fluid. The retention time of ^3^H-RA was 10 min and oxidative metabolites of ^3^H-RA were detected, eluting samples over 3 to 7 min. Metabolism was determined from the % conversion of RA into its total metabolites based on AUC values.

Determination of IC50 values for potent P-450 inhibitors of retinoic acid metabolism
------------------------------------------------------------------------------------

The IC50 values were determined for compounds exhibiting \> 50% inhibition in the preliminary screening at 100 μM.

The incubations were performed in triplicate using varying inhibitor concentrations in DMSO (10 μl) (as determined by preliminary experiments), RA (3 μM, 10 μl), NADPH (2 mM, 50 ml), phosphate buffer (50 mM, pH 7.4, 320 μl) and male rat hepatic microsomes (0.12 mg/ml, 10 μl) at 37°C for 15 min. The reaction was terminated by addition of formic acid (1% 100μl), and HPLC analysis was performed by the method described above. Three separate experiments (each with triplicate tubes) were carried out.

Results
=======

Preliminary screening of P450 inhibitors on the in vitro inhibition of RA metabolism
------------------------------------------------------------------------------------

Forty-one known P450 inhibitors belonging to antifungal (mostly), analgesic, anticoagulant, anticonvulsants, antineoplastics, histamine, antihistamines and some miscellaneous drug classes were tested for their inhibitory activity against RA metabolism. Most of them are nitrogen-containing compounds. The results presented in [table 1](#t1-scipharm-2011-79-921){ref-type="table"} showed that among these compounds only six compounds (*N*-benzyl-2-phenylethanamine, itraconazole, chlorpromazine, 5-chloro-1,3-benzoxazol-2-amine, proadifen and furazolidone) showed inhibition of RA metabolism which was \> 50%. Ketoconazole and liarozole were also screened as standard potent inhibitors in the same system and gave 87.5% and 89% inhibition, respectively.

IC50 values for Potent Inhibitors of RA Metabolism
--------------------------------------------------

The IC50 is the concentration of an inhibitor required to inhibit the enzyme by 50% at a given substrate concentration. IC50 were determined for compounds exhibiting \> 50% inhibition in the preliminary screening at 100 μM. The IC50 for ketoconazole and liarozole were determined for comparative purposes.

The IC50 was calculated from a plot of percentage inhibition versus log inhibitor concentration using Cricket Graph 1.3. These are shown in [Fig 1](#f1-scipharm-2011-79-921){ref-type="fig"}[](#f2-scipharm-2011-79-921){ref-type="fig"}[](#f3-scipharm-2011-79-921){ref-type="fig"}--[4](#f4-scipharm-2011-79-921){ref-type="fig"}. The IC50 values are summarized in [table 2](#t2-scipharm-2011-79-921){ref-type="table"}.

Discussion
==========

Retinoic acid (RA) concentrations either too low or too high (normal serum RA levels 0.5--7.0 ng/ml) adversely affect differentiation and maintenance of the tissues \[[@b18-scipharm-2011-79-921], [@b19-scipharm-2011-79-921]\]. Normal embryonic development also requires RA as a transcriptional regulator during specific times and at specific stages \[[@b20-scipharm-2011-79-921]--[@b22-scipharm-2011-79-921]\].

A dose of 10 mg/Kg body weight of RA has been shown to result in an approximately 50-fold increase in the level of RA in mouse embryo limb buds and generally results in developmental abnormalities. While a dose of 1 mg/Kg, which is approximately 20 times higher than the daily dose of RA necessary to support adequate growth of vitamin A-deficient animals produced no teratogenic effects in mice \[[@b23-scipharm-2011-79-921]\].

Either abnormal concentrations of RA (either higher or lower than normal) or transiently inappropriate RA availability cause central nervous system, limb and craniofacial defects in mice \[[@b23-scipharm-2011-79-921], [@b24-scipharm-2011-79-921]\]. Therefore, maintaining the correct RA concentrations demands tight control over RA biosynthesis and metabolism.

In contrast to retinal, which is stored in tissues and which displays stable plasma levels under regulation from the tissue stores, RA is rapidly metabolized in tissues and rapidly cleared from the plasma (t ½ \< 1h) \[[@b25-scipharm-2011-79-921]\]. A cytochrome P450 (CYP) dependent oxidation in the 4 position of RA appears to be the rate limiting first step in the metabolism of RA to polar metabolites, the latter being biologically less active \[[@b25-scipharm-2011-79-921]--[@b27-scipharm-2011-79-921]\]. The significance of this catabolism of RA in relation to the biological and pharmacological effects of RA has received attention only recently. Warell and co-workers noted that patients who had received exogenous RA chronically to induce the remission of acute promelocytic leukemia (APL) later presented with increased plasma clearance of RA due to induction of metabolism \[[@b28-scipharm-2011-79-921], [@b29-scipharm-2011-79-921]\]. The enhanced plasma clearance of RA may have contributed to the failure of RA therapy to maintain remissions in these APL patients.

Liarozole fumarate is an imidazole cytchrome P450 inhibitor that has been shown to inhibit the metabolism of RA in in vitro tumour systems \[[@b30-scipharm-2011-79-921], [@b31-scipharm-2011-79-921]\]. Liarozole has shown significant antitumour effects in animal models and has clinical benefit in patients with advanced prostate cancers \[[@b32-scipharm-2011-79-921]--[@b34-scipharm-2011-79-921]\]. This anticancer activity owes part of its effectiveness to inhibition of the oxidative metabolism of RA with a concomitant elevation of tumour RA levels. This has opened up the possibility of developing more specific inhibitors of RA metabolism as a novel approach to cancer treatment. In the present investigation a wide range of established P450 inhibitors has been screened to examine their inhibitory activity on RA metabolism.

In the present studies different chemical ligands belonging to different chemical and pharmacological groups have been examined to study their possibility as RA metabolism inhibitor. The results indicate that mostly azoles with substituents in positions other than the 1-position on the ring are very weak inhibitors of RA metabolism. The most effective inhibitors (ketoconazole, itraconazole, bifonazole and clotrimazole) are 1-substituted and possess relatively large aromatic groups in the molecule. This reflects that 1-substituted imidazole bind to cytochrome P-450 with a very high affinity but substitution in the other position of the imidazole decreases the binding affinity.

Njar et al. \[[@b35-scipharm-2011-79-921]\], have explained that introduction of azole group at C-4 of ATRA may yield specific and potent inhibitors of ATRA-4-hydroxylase. Indeed they have described the synthesis of a number of novel 4 azolyl ATRA derivatives, some of which are amongst the most potent inhibitors of this enzyme \[[@b35-scipharm-2011-79-921]\].

Further study of these structure-activity relationships may provide useful lead compounds that could offer a novel approach to cancer treatment.

Although several cytochrome P450 enzymes (CYPs) have been shown to be involved in the catalysis of ATRA 4-hydroxylation, their specificity for ATRA is generally low \[[@b28-scipharm-2011-79-921], [@b36-scipharm-2011-79-921]--[@b39-scipharm-2011-79-921]\]. Recently, a new family of cytochrome P450 enzymes, CYP26A1, has been cloned and characterized in zebra fish, human, and mouse tissues \[[@b40-scipharm-2011-79-921]\]. CYP26A1 is ATRA-inducible and appears to be the most dedicated ATRA 4-hydroxylase enzyme known \[[@b40-scipharm-2011-79-921]\].

The compounds designed to inhibit CYP26A1 activity may be useful in elevating normal tissue ATRA levels or maintaining high therapeutic levels of ATRA. As such, it is an attractive pharmacological target for drug development when one aims to increase circulating or cellular RA concentrations. Further study of structure-activity relationships may provide useful lead compounds that could offer a novel approach to cancer treatment as does by liarozole for the treatment of prostate cancer \[[@b16-scipharm-2011-79-921] \].
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###### 

In vitro inhibition of retinoic acid metabolism by P-450 inhibitors (100 μM). (Values are means of three determinations,(n=3), individual values differ from the mean by less than 3.1%. The symbol (-) denotes stimulation of RA metabolism).

  ---------------------------------------------- ---------------
  **Antifungal Compounds**                       
                                                 
  \(a\) *Imidazoles and related ring systems*    
                                                 
  Compound                                       \% Inhibition
                                                 
  Liarozole                                      89.0
  Ketoconazole                                   87.5
  Itraconazole                                   68.7
  Bifonazole                                     47.5
  Clotrimazole                                   34.4
  Econazole                                      14.0
  Miconazole                                     13.5
  1-Benzylimidazole                              7.6
  Sulconazole                                    8.7
                                                 
  \(a\) *Non imidazoles*                         
                                                 
  Compound                                       \% Inhibition
                                                 
  Griseofulvin                                   0.0
  Amphotericin                                   6.24
  Nystatin                                       5.44
                                                 
  *(c) Oxazoles and Thiazoles*                   
                                                 
  Compound                                       \% Inhibition
                                                 
  2-Methyl-5-phenyl-1,3-benzoxazole              18.0
  4-(4-Bromophenyl)-1,2,3-thiadiazole            11.6
  5-(4-Methylphenyl)-1,2,4-thiadiazole           4.8
  5-(3-Chlorophenyl)-1,3-oxazole                 8.6
  2-(Thiophen-2-yl)-1,3,4-oxadiazole             0.0
  5-Chloro-1,3-benzoxazol-2-amine                86.0
                                                 
  **Anthelmintic** (Azoles)                      
                                                 
  Compound                                       \% Inhibition
                                                 
  Tetramizole HCl                                0.0
  Thiabendazole                                  −4.31
                                                 
  **Anticoagulants** (Coumarin group)            
                                                 
  Compound                                       \% Inhibition
                                                 
  4-Hydroxycoumarin                              38.50
  Coumarin                                       37.0
  7-Methoxycoumarin                              11.7
  S-Warfarin                                     6.5
  R-Warfarin                                     3.0
                                                 
  **Analgesics**                                 
                                                 
  Compound                                       \% Inhibition
                                                 
  Aspirin                                        5.0
  Paracetamol                                    3.5
  Diflunisal                                     2.0
  Indomethacin                                   0.0
  Ketoprofen                                     −3.5
                                                 
  **Antineoplastic** (Aromatase inhibitors)      
                                                 
  Compound                                       \% Inhibition
                                                 
  Aminoglutethimide                              30.8
  Nitroglutethimide                              −1.4
                                                 
  **Anticonvulsants**                            
                                                 
  Compound                                       \% Inhibition
                                                 
  Nafimidone                                     12.0
  Phensuximide                                   3.5
                                                 
  **Histamine and Antihistamines**               
                                                 
  Compound                                       \% Inhibition
                                                 
  Thiopermide maleate                            3.4
  Cimetidine                                     1.0
  Histamine                                      0.0
                                                 
  **Anorectics** (Benzphetamine and analogues)   
                                                 
  Compound                                       \% Inhibition
                                                 
  *N*-Benzyl-2-phenylethanamine                  85.0
  Benzphetamine                                  46.0
                                                 
  **Miscellaneous Compounds**                    
                                                 
  Compound                                       \% Inhibition
                                                 
  Proadifen                                      86.0
  Chlorpromazine                                 85.0
  Furazolidone                                   54.0
  Phenobarbitone                                 0.0
  ---------------------------------------------- ---------------

###### 

IC50 values for some potent P-450 Inhibitors using male rat hepatic microsomes and retinoic acid as substrate (3μM).

  Compound                          IC50 (μM)
  --------------------------------- ------------
  Proadifen                         1.0 ± 0.14
  Liarozole                         4.2 ± 0.1
  5-Chloro-1,3-benzoxazol-2-amine   6.5 ± 0.1
  Ketoconazole                      13.5 ± 1.3
  Chlopromazine                     16.9 ± 1.7
  *N*-Benzyl-2-phenylethanamine     17.1 ± 3.2
  Itraconazole                      17.4 ± 1.0
  Furazolidone                      88.5 ± 6.0

Values are means ± S.D (n=3).
